Many people with hemophilia A can lead ordinary, active lives. Learning more about this genetic condition can support effective long-term management strategies. Hemophilia A is a genetic condition ...

Hemophilia A is a rare, inherited condition that prevents your blood from clotting the way it should. People with hemophilia A do not make enough of a protein called factor VIII, which normally works ...

When Domenic Catrine was born, his heel swelled up from his vitamin K shot. His circumcision site wouldn't stop bleeding. At the Children's Hospital of Philadelphia, Catrine was diagnosed as having ...

What Is Alhemo, and Why Does It Matter? Alhemo (concizumab-mtci) is a medicine approved to help prevent bleeding in people aged 12 or older with hemophilia A or B who don’t have inhibitors to certain ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults ...

ARDEN HILLS, Minn. — An Arden Hills first grader is making a diagnosis a little less scary. Seven-year-old Emmett Cordes was born with a rare blood disorder, but through his love of science and ...

Approval of valoctocogene roxaparvovec for adults with severe hemophilia A was based on data from the global phase III GENEr8-1 study, in which the therapy reduced the average annualized bleeding rate ...

When Allison Sandford-Sweatman’s then four-year-old son Griffin was accidentally kicked in the leg by another player, she felt she had no choice but to pull him out of soccer. As a mom to a child with ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the clearance of its ...

Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis Sangamo is eligible to earn from Pfizer up to $220 million in milestone payments ...

Russell P. Gollard, MD, FACP, discusses coverage decisions for expensive treatments in hemophilia, including total cost of care, drug availability, and real-world evidence. Russell P. Gollard, MD, ...

This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization ...